A significant number of pediatric inflammatory bowel disease patients are exposed to a medication not approved by the Food and Drug Administration for pediatric use
Published August 2025
Therapeutic Drug Monitoring in Pediatric IBD: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers
Published August 2025
Proactive therapeutic drug monitoring (TDM) for tumor necrosis factor alpha antagonist (anti-TNF) therapy in adult inflammatory bowel disease (IBD) remains controversial, with inconsistent findings from clinical trials and meta-analyses. Pediatric societal guidelines endorse the implementation of proactive TDM. However, the integration of TDM into clinical practice by pediatric gastroenterologists has not been characterized. This study was undertaken to delineate the practice patterns, attitudes, and barriers associated with anti-TNF TDM among pediatric gastroenterologists across the United States.
Patient and healthcare professional perspectives on fatigue assessment in pediatric inflammatory bowel disease
Published June 2025
Jennie G. David, Dana Kamara, Nour Al‐Timimi, Valerie McLaughlin Crabtree, Sabina Ali, ImproveCareNow Learning Health System
Pediatric patients with active and quiescent inflammatory bowel disease (IBD) have known fatigue, but there is limited understanding of how fatigue is clinically assessed. This study explored perspectives of pediatric IBD patients and healthcare professionals (HCPs) regarding fatigue assessments.
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Published May 2025
Maltz RM, Saeed SA, Adler J
Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort.
Multicenter study of continuing ustekinumab after intravenous induction reactions in pediatric Crohn's disease
Published May 2025
Joann Samalik, Andrew Singer, Sabina Ali, Archana Anandakrishnan, Michaella K. Baker, Jana Creps, Camila Khorrami, Ross M. Maltz, Lauren Manning, Jonathan Moses, Brad Pasternak, Perseus V. Patel, Dianne C. Singer, David L. Suskind, Becca Trombler, Jeremy Adler
Reactions to intravenous ustekinumab for inflammatory bowel disease (IBD) occur, the frequency of which is uncertain. It is unclear how often subcutaneous treatment is continued after reactions to the intravenous dose, or how well it is tolerated. We therefore conducted a retrospective cohort study of pediatric patients who initiated ustekinumab for Crohn's disease from 6 pediatric IBD centers in the United States.